



ALUNBRIG® is indicated as

monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

ALUNBRIG® is indicated as

monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

ALUNBRIG (BRIGATINIB) AVAILABLE NOW

Reference: Alunbrig® Malaysia Approved Professional Information, June 2020.

For Healthcare Professionals Only.



SCAN HERE

for ALUNBRIG® Abbreviated
Prescribing Information